Oxford University To Conclude Covid-19 Vaccine Trials By Nov-End, Mass Production In 2021

Oxford University's Covid-19 vaccine candidate will have its trials end towards the end of November.

(Representative Image/Getty)

New Delhi: The Covid-19 vaccine being jointly manufactured by Oxford University and AstraZeneca is currently undergoing stage 3 clinical trials which will conclude by November end.  An Oxford official informed about this development. A few days ago, data of the promising early trials were released, which further brought more hope for the vaccine to be given all clear and be available for the public in 2021. The researchers have revealed that this particular Coronavirus vaccine is found to produce a double immune response in people of  18 to 55 of age. Back in July,  Dr. Adrian Hill, director of the Jenner Institute at Oxford University had said, "We are seeing good immune response in almost everybody." As per reports, the vaccine after getting all necessary clearance will have its mass production being only by the first quarter of 2021. Pune's Serum Institute of India (SII) had reached an agreement with the AstraZeneca to produce the vaccine for India. A company official had informed that SII has invested USD 100 million on the Oxford University vaccine candidate. On Tuesday, Russian President Vladimir Putin had announced that Russia has developed the world's first vaccine against Coronavirus. He said the vaccine has been inoculated to his daughter and that it works effectively by forming a stable immunity. However, as the world has cognisance of this breakthrough development, internationally the vaccine has raised many safety concerns among the medical community and if it comes to India it will be looked at critically. WATCH | India will soon develop Corona vaccine: Ashwini Kumar Choubey